D. Boral Capital Reiterates "Buy" Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $25.00 price objective on the stock. D. Boral Capital's price target indicates a potential upside of 148.02% from the company's previous close.

UroGen Pharma Price Performance

Shares of NASDAQ:URGN traded down $0.63 during trading on Tuesday, reaching $10.08. The company had a trading volume of 801,481 shares, compared to its average volume of 355,285. The firm's fifty day moving average is $10.73 and its 200 day moving average is $12.20. The firm has a market capitalization of $236.38 million, a PE ratio of -3.20 and a beta of 1.08. UroGen Pharma has a twelve month low of $9.78 and a twelve month high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

Insider Transactions at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company's stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares of the company's stock, valued at approximately $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.10% of the company's stock.

Institutional Trading of UroGen Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in URGN. KLP Kapitalforvaltning AS acquired a new stake in UroGen Pharma during the fourth quarter valued at approximately $59,000. Lazard Asset Management LLC acquired a new stake in UroGen Pharma during the fourth quarter valued at approximately $67,000. Aquatic Capital Management LLC acquired a new stake in UroGen Pharma during the fourth quarter valued at approximately $101,000. China Universal Asset Management Co. Ltd. lifted its stake in UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock valued at $103,000 after purchasing an additional 3,856 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in UroGen Pharma by 221.8% during the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after purchasing an additional 5,890 shares during the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.